| Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors: a Children’s Oncology Group Study JL Glade Bender, PC Adamson, JM Reid, L Xu, S Baruchel, Y Shaked, ... J Clin Oncol 26 (3), 399-405, 2008 | 270 | 2008 |
| VEGF blocking therapy in the treatment of cancer J Glade-Bender, JJ Kandel, DJ Yamashiro Expert opinion on biological therapy 3 (2), 263-276, 2003 | 258 | 2003 |
| Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of … B Geoerger, HJ Kang, M Yalon-Oren, LV Marshall, C Vezina, A Pappo, ... The Lancet Oncology 21 (1), 121-133, 2020 | 243 | 2020 |
| Irinotecan–temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial R Mody, A Naranjo, C Van Ryn, LY Alice, WB London, BL Shulkin, ... The lancet oncology 18 (7), 946-957, 2017 | 239 | 2017 |
| Multicenter feasibility study of tumor molecular profiling to inform therapeutic decisions in advanced pediatric solid tumors: the individualized cancer therapy (iCat) study MH Harris, SG DuBois, JLG Bender, AR Kim, BD Crompton, E Parker, ... JAMA oncology 2 (5), 608-615, 2016 | 203 | 2016 |
| CUTLL1, a novel human T-cell lymphoma cell line with t (7; 9) rearrangement, aberrant NOTCH1 activation and high sensitivity to γ-secretase inhibitors T Palomero, KC Barnes, PJ Real, JL Glade Bender, ML Sulis, VV Murty, ... Leukemia 20 (7), 1279-1287, 2006 | 174 | 2006 |
| Implementation of next generation sequencing into pediatric hematology-oncology practice: moving beyond actionable alterations JA Oberg, JL Glade Bender, ML Sulis, D Pendrick, AN Sireci, SJ Hsiao, ... Genome medicine 8, 1-19, 2016 | 173 | 2016 |
| Phase I pharmacokinetic and pharmacodynamic study of pazopanib in children with soft tissue sarcoma and other refractory solid tumors: a children's oncology group phase I … JL Glade Bender, A Lee, JM Reid, S Baruchel, T Roberts, SD Voss, B Wu, ... Journal of clinical oncology 31 (24), 3034-3043, 2013 | 169 | 2013 |
| Phase I study of bortezomib combined with chemotherapy in children with relapsed childhood acute lymphoblastic leukemia (ALL): a report from the therapeutic advances in … Y Messinger, P Gaynon, E Raetz, R Hutchinson, S DuBois, ... Pediatric blood & cancer 55 (2), 254-259, 2010 | 136 | 2010 |
| Irinotecan, temozolomide, and dinutuximab with GM-CSF in children with refractory or relapsed neuroblastoma: a report from the Children’s Oncology Group R Mody, AL Yu, A Naranjo, FF Zhang, WB London, BL Shulkin, MT Parisi, ... Journal of Clinical Oncology 38 (19), 2160-2169, 2020 | 132 | 2020 |
| Recurrent EML4–NTRK3 fusions in infantile fibrosarcoma and congenital mesoblastic nephroma suggest a revised testing strategy AJ Church, ML Calicchio, V Nardi, A Skalova, A Pinto, DA Dillon, ... Modern Pathology 31 (3), 463-473, 2018 | 131 | 2018 |
| Phase I and pharmacokinetic study of sunitinib in pediatric patients with refractory solid tumors: a children's oncology group study SG DuBois, S Shusterman, AM Ingle, CH Ahern, JM Reid, B Wu, ... Clinical Cancer Research 17 (15), 5113-5122, 2011 | 126 | 2011 |
| Vascular remodeling and clinical resistance to antiangiogenic cancer therapy JG Bender, EM Cooney, JJ Kandel, DJ Yamashiro Drug Resistance Updates 7 (4-5), 289-300, 2004 | 120 | 2004 |
| A phase I trial and pharmacokinetic study of sorafenib in children with refractory solid tumors or leukemias: a Children's Oncology Group Phase I Consortium report BC Widemann, AR Kim, E Fox, S Baruchel, PC Adamson, AM Ingle, ... Clinical Cancer Research 18 (21), 6011-6022, 2012 | 119 | 2012 |
| Efficacy of systemic sirolimus in the treatment of generalized lymphatic anomaly and Gorham–Stout disease KW Ricci, AM Hammill, P Mobberley‐Schuman, SC Nelson, J Blatt, ... Pediatric blood & cancer 66 (5), e27614, 2019 | 107 | 2019 |
| Prospective pan-cancer germline testing using MSK-IMPACT informs clinical translation in 751 patients with pediatric solid tumors EM Fiala, G Jayakumaran, A Mauguen, JA Kennedy, N Bouvier, Y Kemel, ... Nature cancer 2 (3), 357-365, 2021 | 91 | 2021 |
| Angiogenesis and vascular targeting in Ewing sarcoma: a review of preclinical and clinical data SG DuBois, N Marina, J Glade‐Bender Cancer: Interdisciplinary International Journal of the American Cancer …, 2010 | 90 | 2010 |
| Anti-HPA-3A induces severe neonatal alloimmune thrombocytopenia J Glade-Bender, JG McFarland, C Kaplan, L Porcelijn, JB Bussel The Journal of pediatrics 138 (6), 862-867, 2001 | 88 | 2001 |
| Clinical sequencing of soft tissue and bone sarcomas delineates diverse genomic landscapes and potential therapeutic targets BA Nacev, F Sanchez-Vega, SA Smith, CR Antonescu, E Rosenbaum, ... Nature Communications 13 (1), 3405, 2022 | 81 | 2022 |
| Emerging novel agents for patients with advanced Ewing sarcoma: A report from the Children’s Oncology Group (COG) New Agents for Ewing Sarcoma Task Force K Bailey, C Cost, I Davis, J Glade-Bender, P Grohar, P Houghton, ... F1000Research 8, 2019 | 67 | 2019 |
Susan BlaneyProfessor of Pediatrics, Baylor College of MedicineVerified email at bcm.edu
